X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5503) 5503
Publication (512) 512
Newsletter (126) 126
Book Review (71) 71
Book Chapter (47) 47
Magazine Article (15) 15
Conference Proceeding (12) 12
Book / eBook (10) 10
Dissertation (4) 4
Newspaper Article (2) 2
Data Set (1) 1
Government Document (1) 1
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3491) 3491
index medicus (2623) 2623
animals (2109) 2109
male (2012) 2012
amides - therapeutic use (1965) 1965
female (1699) 1699
amides (1174) 1174
pharmacology & pharmacy (1075) 1075
middle aged (1012) 1012
amides - pharmacology (882) 882
adult (871) 871
mice (790) 790
aged (751) 751
rats (736) 736
amides - administration & dosage (659) 659
antihypertensive agents - therapeutic use (545) 545
fumarates - therapeutic use (514) 514
treatment outcome (513) 513
acid amide hydrolase (501) 501
chemistry, medicinal (466) 466
amides - chemistry (462) 462
analysis (435) 435
amides - adverse effects (432) 432
anesthetics, local - therapeutic use (422) 422
research (417) 417
double-blind method (393) 393
neurosciences (389) 389
hypertension - drug therapy (370) 370
medicine (367) 367
renin - antagonists & inhibitors (366) 366
dose-response relationship, drug (358) 358
pain (351) 351
anesthetics, local - administration & dosage (343) 343
biochemistry & molecular biology (341) 341
anesthesiology (337) 337
ropivacaine (334) 334
structure-activity relationship (334) 334
hypertension (333) 333
research article (331) 331
care and treatment (319) 319
prospective studies (316) 316
endocannabinoids (315) 315
multidisciplinary sciences (311) 311
disease models, animal (310) 310
drug therapy, combination (308) 308
time factors (307) 307
pain measurement (303) 303
health aspects (302) 302
enzymes (301) 301
surgery (295) 295
article (293) 293
pain, postoperative - drug therapy (289) 289
aliskiren (275) 275
lipids (256) 256
science (247) 247
blood pressure - drug effects (245) 245
anandamide (244) 244
proteins (242) 242
physiological aspects (239) 239
cloprostenol - analogs & derivatives (236) 236
endocannabinoid system (236) 236
pyridines - pharmacology (235) 235
bimatoprost (234) 234
pharmacology (232) 232
adolescent (227) 227
antibiotics (224) 224
inflammation (221) 221
endocrinology & metabolism (220) 220
fumarates - pharmacology (219) 219
rats, sprague-dawley (218) 218
analgesics, opioid - therapeutic use (216) 216
in-vitro (216) 216
drugs (215) 215
drug therapy (213) 213
enzyme inhibitors - pharmacology (212) 212
analgesia (211) 211
antihypertensive agents - adverse effects (210) 210
bupivacaine (204) 204
cancer (201) 201
efficacy (200) 200
pain, postoperative - prevention & control (200) 200
molecular structure (197) 197
rodents (194) 194
chemistry, organic (193) 193
fatty acids (193) 193
renin-angiotensin system - drug effects (190) 190
inhibition (187) 187
aged, 80 and over (186) 186
amides - chemical synthesis (186) 186
peripheral vascular disease (184) 184
diabetes mellitus, type 2 - drug therapy (183) 183
chemistry, multidisciplinary (180) 180
cannabinoids (179) 179
nerve block - methods (177) 177
cell biology (175) 175
intraocular pressure - drug effects (175) 175
ophthalmology (174) 174
rats, wistar (174) 174
mice, inbred c57bl (173) 173
anesthesia (172) 172
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5196) 5196
German (117) 117
French (74) 74
Russian (67) 67
Italian (57) 57
Spanish (51) 51
Japanese (43) 43
Portuguese (28) 28
Chinese (25) 25
Polish (11) 11
Romanian (9) 9
Turkish (6) 6
Czech (4) 4
Danish (2) 2
Norwegian (2) 2
Slovak (2) 2
Ukrainian (2) 2
Dutch (1) 1
Hebrew (1) 1
Hungarian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Therapeutics, ISSN 0149-2918, 09/2018, Volume 40, Issue 9, pp. 1457 - 1466
Journal Article
Expert Review of Clinical Pharmacology, ISSN 1751-2433, 04/2017, Volume 10, Issue 4, pp. 443 - 455
Introduction: The complexity of the endocannabinoid (eCB) system is becoming better understood and new drivers of eCB signaling are emerging. Modulation of the... 
cannabis | Cannabidiol | delta-9-tetrahydrocannabinol | endocannabinoid system | spasticity | multiple sclerosis | GUIDELINE DEVELOPMENT SUBCOMMITTEE | ALZHEIMERS-DISEASE | CB2 RECEPTOR | AMYLOID PATHOLOGY | MULTIPLE-SCLEROSIS SPASTICITY | NEUROPATHIC PAIN | ACID AMIDE HYDROLASE | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | PLACEBO-CONTROLLED TRIAL
Journal Article
Circulation: Heart Failure, ISSN 1941-3289, 10/2017, Volume 10, Issue 10
BACKGROUND: Patients with heart failure (HF) and atrial fibrillation (AF) have higher circulating levels of NT-proBNP (N-terminal pro-B-type natriuretic... 
heart failure | natriuretic peptide, brain | atrial fibrillation | TRIAL | NEPRILYSIN | CARDIAC & CARDIOVASCULAR SYSTEMS | INHIBITION | ALISKIREN | ENALAPRIL | Prognosis | Humans | Middle Aged | Heart Failure - physiopathology | Hospitalization - statistics & numerical data | Male | Heart Failure - blood | Aminobutyrates - therapeutic use | Enalapril - therapeutic use | Case-Control Studies | Peptide Fragments - blood | Cardiovascular Diseases - mortality | Female | Natriuretic Peptide, Brain - blood | Heart Failure - complications | Fumarates - therapeutic use | Atrial Fibrillation - complications | Amides - therapeutic use | Antihypertensive Agents - therapeutic use | Heart Failure - drug therapy | Atrial Fibrillation - blood | Stroke Volume | Tetrazoles - therapeutic use | Aged | Angiotensin Receptor Antagonists - therapeutic use | Cohort Studies | Cardiovascular Diseases/mortality | Atrial Fibrillation/blood/complications | Amides/therapeutic use | Klinisk medicin | Tetrazoles/therapeutic use | Fumarates/therapeutic use | Aminobutyrates/therapeutic use | Hospitalization/statistics & numerical data | Angiotensin Receptor Antagonists/therapeutic use | Heart Failure/blood/complications/drug therapy/physiopathology | Natriuretic Peptide | Antihypertensive Agents/therapeutic use | Enalapril/therapeutic use | Brain/blood | Clinical Medicine | Peptide Fragments/blood
Journal Article
The Journal of Bone & Joint Surgery, ISSN 0021-9355, 02/2013, Volume 95, Issue 4, pp. 291 - 296
BACKGROUND:Appropriate pain management affects outcome after hip fracture surgery. Although multimodal pain management is commonly used for pain control for... 
KNEE | SURGERY | DEMENTIA | TOTAL JOINT ARTHROPLASTY | DELIRIUM | HOSPITAL STAY | LOCAL INFILTRATION ANALGESIA | ELDERLY PATIENTS | ORTHOPEDICS | PUMP | CONSUMPTION | POSTOPERATIVE PAIN | Fentanyl - administration & dosage | Single-Blind Method | Hip Fractures - surgery | Pyrazoles - therapeutic use | Prospective Studies | Fentanyl - therapeutic use | Humans | Male | Adrenergic alpha-Agonists - therapeutic use | Arthroplasty, Replacement, Hip - methods | Adrenergic alpha-Agonists - administration & dosage | Epinephrine - therapeutic use | Cyclooxygenase 2 Inhibitors - therapeutic use | Statistics, Nonparametric | Aged, 80 and over | Anesthetics, Local - therapeutic use | Anesthetics, Local - administration & dosage | Oxycodone - therapeutic use | Oxycodone - administration & dosage | Cyclooxygenase 2 Inhibitors - administration & dosage | Pain Management - methods | Analgesics, Opioid - therapeutic use | Anti-Bacterial Agents - administration & dosage | Morphine - administration & dosage | Sulfonamides - administration & dosage | Ketorolac - therapeutic use | Pain, Postoperative - drug therapy | Epinephrine - administration & dosage | Patient Satisfaction | Anti-Bacterial Agents - therapeutic use | Cefmetazole - therapeutic use | Female | Drug Therapy, Combination | Analgesia, Patient-Controlled | Treatment Outcome | Amides - therapeutic use | Celecoxib | Chi-Square Distribution | Pyrazoles - administration & dosage | Sulfonamides - therapeutic use | Analgesics, Opioid - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Injections, Intra-Articular | Aged | Ketorolac - administration & dosage | Pain Measurement | Amides - administration & dosage | Morphine - therapeutic use | Cefmetazole - administration & dosage
Journal Article
Journal Article
The Lancet, ISSN 0140-6736, 2006, Volume 368, Issue 9548, pp. 1696 - 1705
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and... 
MEDICINE, GENERAL & INTERNAL | IN-VITRO | METFORMIN-TREATED PATIENTS | HEALTHY-SUBJECTS | 2ND-PHASE INSULIN-SECRETION | IMPROVES GLYCEMIC CONTROL | BETA-CELL APOPTOSIS | IV INHIBITOR | 7-36 AMIDE | IMPROVED GLUCOSE-TOLERANCE | EXENATIDE SYNTHETIC EXENDIN-4 | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Pyrazines - administration & dosage | Glucagon-Like Peptide 1 - biosynthesis | Dipeptidyl Peptidase 4 | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Pyrrolidines | Venoms - administration & dosage | Nitriles | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Glucagon-Like Peptide 1 - classification | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glycoproteins - antagonists & inhibitors | Clinical Trials as Topic | Glucagon-Like Peptide-1 Receptor | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Venoms - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Diagnosis | Glucagon | Analysis | Dosage and administration | Research | Protease inhibitors | Drug therapy | Proteins | Diabetes | Kinases | Insulin | Rodents
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2012, Volume 367, Issue 23, pp. 2204 - 2213
Patients with type 2 diabetes at high risk for cardiovascular disease who were already taking a renin–angiotensin system blocker were randomly assigned to the... 
GLOMERULAR-FILTRATION-RATE | CHRONIC HEART-FAILURE | MEDICINE, GENERAL & INTERNAL | CONVERTING-ENZYME INHIBITORS | LEFT-VENTRICULAR DYSFUNCTION | MYOCARDIAL-INFARCTION | DOUBLE-BLIND | CARDIOVASCULAR MORTALITY | FOLLOW-UP | SYSTOLIC DYSFUNCTION | BLOOD-PRESSURE | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Patient Dropouts | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Kidney Diseases - epidemiology | Treatment Failure | Amides - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Hypokalemia | Female | Drug Therapy, Combination | Diabetes Mellitus, Type 2 - complications | Double-Blind Method | Fumarates - therapeutic use | Kidney Diseases - prevention & control | Amides - therapeutic use | Fumarates - adverse effects | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Renin - antagonists & inhibitors | Hyperkalemia - chemically induced | Aged | Kidney Diseases - etiology | Diabetes Mellitus, Type 2 - drug therapy | Angiotensin Receptor Antagonists - therapeutic use | Myocardial infarction | Women | Creatinine | Cerebral infarction | End-stage renal disease | Stroke | Heart attacks | Kidneys | Diabetes mellitus | Cardiovascular disease | Coronary artery disease | Hypotension | Hyperkalemia | Renin | Angiotensin | Renal failure | Diabetes | Kidney diseases | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Heart diseases | Kidney transplantation
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 02/2013, Volume 48, Issue 3, pp. 453 - 463
Piplartine (piperlongumine, 5,6-dihydro-1-[(2 )-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-2(1H)-pyridinone) is a biologically active alkaloid/amide from... 
Piperaceae | Piperlongumine | Long pepper | Piplartine | Ayurvedic medicine | Anticancer activity | TUBERCULATUM | MOLECULAR-STRUCTURE | CELL PROLIFERATION | INHIBITION | BIOSYNTHESIS | PIPER-LONGUM L | ANTIFUNGAL AMIDES | PHARMACOLOGY & PHARMACY | ATHEROSCLEROTIC PLAQUE-FORMATION | ALDOSE REDUCTASE | CYTOTOXIC PYRIDONE ALKALOIDS | Medicine, Ayurvedic | Neoplasms - metabolism | Drugs, Investigational - pharmacology | Fruit - chemistry | Humans | Drugs, Investigational - pharmacokinetics | Drugs, Investigational - therapeutic use | Biological Availability | Drugs, Investigational - metabolism | Piperidones - therapeutic use | Piperidones - pharmacology | Piperidones - pharmacokinetics | Patents as Topic | Piper - chemistry | Neoplasms - drug therapy | Animals | Antineoplastic Agents, Phytogenic - metabolism | Piperidones - metabolism | Antineoplastic Agents, Phytogenic - pharmacology | Antineoplastic Agents, Phytogenic - therapeutic use | Antineoplastic Agents, Phytogenic - pharmacokinetics | Tyrosine | Platelet-derived growth factor | Leukemia | Aspartate | Annexins | Chromatography | Cells | Endothelium | Glutathione transferase | Cell death | Analysis | Lymphomas | Tumor proteins | Health aspects | Vascular endothelial growth factor | Mass spectrometry | Intermediate filament proteins | Phosphotransferases | Fluorouracil
Journal Article